Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA, Rafaeloff-Phail R, Rafizadeh-Montrose C, Rhodes G, Robey R, Rojo I, Rungta D, Snyder D, Wilbur K, Zhang T, Zink R, Warshawsky A, Brozinick JT. Reifel-Miller A, et al. Among authors: brozinick jt. Mol Endocrinol. 2005 Jun;19(6):1593-605. doi: 10.1210/me.2005-0015. Epub 2005 Apr 14. Mol Endocrinol. 2005. PMID: 15831517
A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR Jr, Ogilvie KM, Liu S, Kauffman RF. Etgen GJ, et al. Among authors: brozinick jt. Diabetes. 2002 Apr;51(4):1083-7. doi: 10.2337/diabetes.51.4.1083. Diabetes. 2002. PMID: 11916929
2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.
Martín JA, Brooks DA, Prieto L, González R, Torrado A, Rojo I, López de Uralde B, Lamas C, Ferritto R, Dolores Martín-Ortega M, Agejas J, Parra F, Rizzo JR, Rhodes GA, Robey RL, Alt CA, Wendel SR, Zhang TY, Reifel-Miller A, Montrose-Rafizadeh C, Brozinick JT, Hawkins E, Misener EA, Briere DA, Ardecky R, Fraser JD, Warshawsky AM. Martín JA, et al. Among authors: brozinick jt. Bioorg Med Chem Lett. 2005 Jan 3;15(1):51-5. doi: 10.1016/j.bmcl.2004.10.042. Bioorg Med Chem Lett. 2005. PMID: 15582409
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
Henry JR, Li Y, Warshawsky AM, Brozinick JT, Hawkins ED, Misener EA, Briere DA, Montrose-Rafizadeh C, Zink RW, Yumibe NP, Ajamie RT, Wilken B, Devanarayan V. Henry JR, et al. Among authors: brozinick jt. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6293-7. doi: 10.1016/j.bmcl.2006.09.028. Epub 2006 Sep 26. Bioorg Med Chem Lett. 2006. PMID: 17005393
Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands.
Warshawsky AM, Alt CA, Brozinick JT, Harkness AR, Hawkins ED, Henry JR, Matthews DP, Miller AR, Misener EA, Montrose-Rafizadeh C, Rhodes GA, Shen Q, Vance JA, Udodong UE, Wang M, Zhang TY, Zink RW. Warshawsky AM, et al. Among authors: brozinick jt. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6328-33. doi: 10.1016/j.bmcl.2006.09.011. Epub 2006 Sep 26. Bioorg Med Chem Lett. 2006. PMID: 17005394
FGF-21 as a novel metabolic regulator.
Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB. Kharitonenkov A, et al. Among authors: brozinick jt. J Clin Invest. 2005 Jun;115(6):1627-35. doi: 10.1172/JCI23606. Epub 2005 May 2. J Clin Invest. 2005. PMID: 15902306 Free PMC article.
Genetic ablation of myelin protein zero-like 3 in mice increases energy expenditure, improves glycemic control, and reduces hepatic lipid synthesis.
Czyzyk TA, Andrews JL, Coskun T, Wade MR, Hawkins ED, Lockwood JF, Varga G, Sahr AE, Chen Y, Brozinick JT, Kikly K, Statnick MA. Czyzyk TA, et al. Among authors: brozinick jt. Am J Physiol Endocrinol Metab. 2013 Jul 15;305(2):E282-92. doi: 10.1152/ajpendo.00228.2013. Epub 2013 May 28. Am J Physiol Endocrinol Metab. 2013. PMID: 23715724 Free article.
79 results